Jeff Yass’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-473,543
| Closed | -$10.2M | – | 13576 |
|
|
2026
Q1 | $10.2M | Sell |
473,543
-264,117
| -36% | -$3.72M | ﹤0.01% | 3097 |
|
|
2025
Q4 | $6.87M | Buy |
737,660
+708,806
| +2,457% | +$5.92M | ﹤0.01% | 3559 |
|
|
2025
Q3 | $203K | Sell |
28,854
-71,648
| -71% | -$493K | ﹤0.01% | 10957 |
|
|
2025
Q2 | $653K | Sell |
100,502
-8,066
| -7% | -$55.5K | ﹤0.01% | 8543 |
|
|
2025
Q1 | $861K | Buy |
108,568
+44,314
| +69% | +$477K | ﹤0.01% | 7633 |
|
|
2024
Q4 | $814K | Sell |
64,254
-407
| -0.6% | -$5.66K | ﹤0.01% | 7475 |
|
|
2024
Q3 | $901K | Sell |
64,661
-26,437
| -29% | -$377K | ﹤0.01% | 7037 |
|
|
2024
Q2 | $1.26M | Buy |
91,098
+16,944
| +23% | +$248K | ﹤0.01% | 6046 |
|
|
2024
Q1 | $1.23M | Buy |
74,154
+26,776
| +57% | +$401K | ﹤0.01% | 6407 |
|
|
2023
Q4 | $692K | Sell |
47,378
-7,358
| -13% | -$89.2K | ﹤0.01% | 7870 |
|
|
2023
Q3 | $672K | Sell |
54,736
-25,334
| -32% | -$330K | ﹤0.01% | 7545 |
|
|
2023
Q2 | $956K | Sell |
80,070
-21,208
| -21% | -$277K | ﹤0.01% | 6780 |
|
|
2023
Q1 | $1.35M | Buy |
101,278
+80,710
| +392% | +$1.58M | ﹤0.01% | 6055 |
|
|
2022
Q4 | $443K | Sell |
20,568
-28,800
| -58% | -$591K | ﹤0.01% | 8188 |
|
|
2022
Q3 | $989K | Buy |
+49,368
| New | +$1.05M | ﹤0.01% | 6656 |
|
|
2022
Q2 | – | Sell |
-18,604
| Closed | -$192K | – | 13052 |
|
|
2022
Q1 | $185K | Buy |
+18,604
| New | +$246K | ﹤0.01% | 11324 |
|
Other funds holding DAWN
Jeff Yass's DAWN Position: Q2 2026 in Review
Jeff Yass sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 473,543 shares — an estimated $10.2M sold.
Jeff Yass first reported a position in DAWN in Q1 2022 and held it in 16 quarters. The position peaked at $10.2M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Jeff Yass reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 473,543 Day One Biopharmaceuticals shares in Q2 2026, an estimated $10.2M.
- Jeff Yass first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 16 quarters.
- Jeff Yass's Day One Biopharmaceuticals position peaked at $10.2M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.